AstraZeneca inks billion dollar deal with Chinese startup Eccogene

China-based startup Eccogene has entered into an exclusive license agreement with UK-based pharmaceutical firm AstraZeneca to develop and commercialise Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities.

Preliminary results from the Phase I trial have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo.

GLP-1RAs are an important treatment option for people living with metabolic diseases such as diabetes and obesity. They have been shown to be effective at decreasing haemoglobin A1c (HbA1c), promoting weight loss and reducing the risk of cardiovascular events by mimicking the hormone GLP-1.

Under the terms of the agreement, Eccogene will receive an initial upfront payment of $185 million. In addition, Eccogene will be eligible to receive up to an additional $1.825 billion in future clinical, regulatory, and commercial milestones. Eccogene is further eligible to receive tiered royalties on net product sales.

In exchange, AstraZeneca will receive exclusive rights to develop and commercialise Eccogene's ECC5004 small molecule GLP-1RA for any indication in all territories except China. Eccogene and AstraZeneca will partner for co-development and co-commercialisation of ECC5004 in China.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!